Finding a cure requires leadership that can look beyond the horizon.
Innovation for the Most Urgent Medical Needs
Genovyn’s discovery and development model leads to improved success rates and significantly reduces development time and cost to market. Genovyn’s companies are therapeutically focused, tactically nimble, and benefit from operational efficiencies provided centrally by Genovyn. Our subsidiaries or “Vyns” and their leadership teams are Therapeutically aligned experts focused on the development mission.
We are rethinking traditional drug development by pioneering therapies designed to move beyond conventional pathways, unlocking new possibilities where options have long been limited. Guided by innovation, collaboration, and an unwavering commitment to patients, Genovyn is charting a bold course toward a future where devastating diseases can be met with real solutions.
Our Business Model
Genovyn’s integrated discovery and development model enhances program success rates while reducing both time and cost to market. Our portfolio companies—known as “Vyns”—are therapeutically focused and operationally agile, leveraging the centralized infrastructure, resources, and expertise of the Genovyn platform.
Each Vyn is led by seasoned domain experts aligned around a clear therapeutic mission, combining scientific rigor with strategic execution. This structure enables Genovyn to scale innovation efficiently across diverse therapeutic areas while maintaining focus, speed, and capital discipline.
Unmatched Leadership
Genovyn is led by a dynamic and driven leadership team dedicated to transforming cutting-edge science into life-changing therapies. With deep expertise spanning drug discovery, clinical development, and regulatory strategy, we are focused on addressing critical unmet needs in oncology and immunology. Our mission is to advance innovative drug candidates from concept to commercialization, accelerating the path from scientific discovery to meaningful patient impact.
Chairman & Chief Executive Officer | Genovyn
Jeff is a global life sciences executive with more than 30 years of experience spanning biotechnology, clinical research, and pharmaceutical commercialization. As Chairman and CEO of Genovyn, he leads the company’s mission to advance innovative therapeutic platforms through scientific excellence, strategic partnerships, and operational precision.
With a deep expertise in clinical development and global commercialization, Jeff has guided organizations through every phase of growth—from early clinical strategy and regulatory execution to global market expansion.
Chief Financial & Business Officer | Genovyn
Jeff Reiniche is an accomplished finance and strategy executive with extensive experience in biotechnology, clinical research, and corporate growth. As Chief Financial and Business Officer of Genovyn, he oversees financial strategy, capital development, and M&A initiatives that align innovation with sustainable enterprise value. Jeff previously served as CFO at Inclinix and held senior leadership roles at Click Commerce and PricewaterhouseCoopers, guiding large-scale transactions and integrations. Over his career, he has led investments and acquisitions ranging from $10 million to $2 billion, recognized for combining financial rigor with strategic insight to drive growth across the life sciences sector.
Chief Scientific Officer | Genovyn
Dr. Sammy Bell serves as Chief Scientific Officer at Genovyn, where he leads scientific strategy, AI platform integration, discovery enablement, and portfolio advancement. He is responsible for translating AI-driven insights into biological validation and therapeutic discovery, accelerating candidate prioritization, and advancing Genovyn’s pipeline toward clinical development.
Dr. Bell brings more than 23 years of pharmaceutical R&D leadership spanning discovery through early clinical development across small molecules, peptides, oligonucleotides, and targeted protein degraders (PROTACs). Prior to joining Genovyn, he served as Associate Vice President of Early Phase Drug Development at Eli Lilly, where he led a global organization responsible for early-phase development across a broad portfolio of therapeutic programs. He previously held senior leadership roles at Boehringer Ingelheim, Novartis, and Pfizer, leading discovery integration, formulation sciences, CMC strategy, and translational drug development across multiple therapeutic areas.
Chief Development Officer | Genovyn
Dr. Jim Edinger serves as Chief Development Officer at Genovyn, where he leads translational strategy, preclinical development, and program execution to advance therapeutic candidates toward key development milestones. He oversees the progression of programs from discovery through IND-enabling activities and future clinical readiness.
Dr. Edinger brings more than 20 years of biotechnology leadership experience advancing cell and gene therapy programs from concept through IND and early clinical execution. Prior to Genovyn, he served as Chief Scientific Officer and SVP of R&D at Mustang Bio and held leadership positions at Celularity and Celgene Cellular Therapeutics, where he advanced therapeutic programs across oncology, autoimmune, neurological, and rare diseases. He has led more than 10 FDA-accepted IND submissions and built multidisciplinary teams spanning translational science, preclinical pharmacology, manufacturing, and regulatory development.
Our Advisory Board
Chairman and CEO at Ignite BioMedical
Practicing Oncologist, Speaker, and former Head of Oncology for Regeneron
Chief Operating Officer for North America at Miltenyi Biomedicine
Chief Operating Officer at CureLab
Rare Disease, Endocrinology & Metabolic Executive at Pfizer
About the “-vyn”
The “-vyn” suffix unites each of our portfolio companies under a shared vision: to develop and deliver transformative therapies. While each “vyn” operates with focus and autonomy, all are built on a common platform—aligned in science, strategy, and purpose. Together, they form a cohesive ecosystem aimed at improving lives through innovation.
